ClinicalTrials.gg
RecruitingNCT07849023Updated Sep 30, 2026

Application of Precision Partial Intersphincteric Resection (PPISR)

An interventional study of Precision Partial Intersphincteric Resection (PPISR) and Traditional Intersphincteric Resection in Low Rectal Cancer and Rectal Cancer Patients, sponsored by First Affiliated Hospital of Wenzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by First Affiliated Hospital of Wenzhou Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2026, registered May 2026).
  • Started Feb 2026; still recruiting 9 months later.
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 463 studies in Rectal Neoplasms with a site in China — 228 open to participants now, 267 under way, 42 of them phase 3. Rectal Neoplasms · China.

Planned enrollment
175th of 373
100 · median 100
Started
2026
with 50 others
No phase
133 of 463
58 open now
Primary completion
2027-06
later than 160 of 266 live
Registered
432nd of 463
by date

Among the 463 studies in Rectal Neoplasms with a site in China, this one is the 175th largest by planned enrollment of the 373 interventional ones that give a count, is one of 51 that started in 2026, is one of 133 with no phase, reaches primary completion later than 160 of the 266 other live ones, and was the 432nd registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

228 of the 463 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

223 more — sign in →

All 228 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to establish a standardized operating procedure for Precision Partial Intersphincteric Resection (PPISR), and to evaluate its surgical safety, functional benefits, and oncological efficacy.

03

Conditions studied

  • Low Rectal Cancer
  • Rectal Cancer Patients

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-75 years old
  • Pathology suggestive of moderately to highly differentiated rectal adenocarcinoma
  • Tumor lower margin ≤ 5 cm from the anal verge
  • Pre-operative tumor (T) staging of T1-T3 and T1-T2 below the level of the anal raphe muscle
  • No distant such as lung, liver and other organs

Exclusion criteria

Exclusion Criteria:

  • Preoperative patients with severe underlying diseases (such as severe liver and kidney function, cardiopulmonary function, coagulation dysfunction, etc.)
  • Patients with malignant tumors in other parts of the body
  • Patients who underwent emergency surgery due to acute perforation, obstruction, etc.
  • Patients with tumor infiltration of peripheral organs during the operation, which required combined resection or palliative resection
  • Patients who had a mid-opening laparoscopic operation for various reasons -during the operation
  • Patients with poor anal function before operation, which is not suitable for anus preservation surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    PPISR

    The experimental group underwent the PPISR procedure.

    Procedure: Precision Partial Intersphincteric Resection (PPISR)

  • Active comparator
    Traditional ISR

    The control group underwent the traditional ISR procedure

    Procedure: Traditional Intersphincteric Resection

Interventions

  • ProcedurePrecision Partial Intersphincteric Resection (PPISR)

    The experimental group underwent the PPISR procedure. The surgical process was as follows: 1. The abdominal team performed the TME procedure, completely resecting the mesorectum at the level of the mesorectum termination line within the levator hiatus. 2. The transanal team completed routine preoperative preparation and disinfection, and located the distal and lateral resection margins of the tumor (with a margin distance ≥5 mm from the tumor boundary), thereby preserving part of the internal anal sphincter and normal intestinal wall tissue. 3. A "U"-shaped dissection was performed cranially along the marking line within the intersphincteric space, meeting the abdominal team at the level of the levator hiatus, as shown in Figure 1. 4. The specimen was removed either transanally or transabdominally. 5. The proximal intestinal segment was trimmed, intestinal anastomosis was performed manually, and the procedure was concluded.

  • ProcedureTraditional Intersphincteric Resection

    The control group underwent the traditional ISR procedure. The surgical process was as follows: 1. The abdominal team entered the abdominal cavity and mobilized the sigmoid colon and rectum according to the principle of total mesorectal excision (TME). The vessels were ligated at a high position, and the rectum was dissected downward along the presacral space to the level of the levator ani muscle (pelvic floor), fully exposing the distal rectum and the levator ani muscle. 2. The transanal team made a full-thickness circumferential incision in the rectal mucosa slightly above the dentate line (approximately ≥1 cm), entering the intersphincteric groove. A sharp circumferential dissection was performed along this groove to "pull" the rectum (along with its internal sphincter) out from within the external anal sphincter. During this dissection, care was taken to avoid damaging the external sphincter complex and its innervation. 3. When the perineal dissection plane reached the level of

06

What researchers measure

Primary outcomes

  1. Postoperative anal function as assessed by Wexner Score

    Scale Title: Wexner Fecal Incontinence Score. The minimum values:0. The maximum values:20. Higher scores mean a worse outcome.

    Time frame: At 3 and 6 months postoperatively

  2. Postoperative quality of life as assessed by EORTC QLQ-C30

    Scale Title: European Organization for Research and Treatment of cancer Quality of Life Questionnaire. The minimum values:0. The maximum values:100. Higher scores mean a worse outcome.

    Time frame: At 1 year postoperatively

  3. 3-year local recurrence rate as assessed by abdominal contrast-enhanced MRI

    Participants have an MRI every 3 months postoperatively

    Time frame: 3 years postoperatively

Secondary outcomes

  1. Circumferential resection margin negative rate

    Time frame: Immediately after the pathology results come out

  2. intraoperative blood loss

    Time frame: Immediately after the surgery

  3. Postoperative-related complication incidence

    Complications include postoperative bleeding, abdominal cavity infection, thoracic cavity infection, urinary tract infection, etc.

    Time frame: From the end of surgery to 3 months postoperatively

  4. Postoperative hospital stay duration

    Time frame: From the end of surgery to discharge

07

Study locations

1 of 1 sites recruiting
  • First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    Recruiting
    • chunwu zhang · Contact86+0577-55578055
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 16 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
Sep 30, 2026
StartActual
Feb 8, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2030
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849023
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Feb 8, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2030 (estimated)
Last update
Sep 30, 2026

Study contacts

shaotang li
Contact
lishaotang163@163.com
86+18815039766

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion